Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC

Cannabis and Cannabinoid Research, Journal Year: 2021, Volume and Issue: 8(1), P. 166 - 173

Published: Nov. 19, 2021

Introduction: Cannabis products containing delta-8-THC became widely available in most of the United States late 2020 and rapidly a significant source revenue for hemp processing companies, especially states where use delta-9-THC remains illegal or requires professional authorization medical use. Scientific research on is scarce, previous clinical studies included combined total 14 participants, leading some state governments to prohibit it until its properties effects are better understood. Methods: Researchers developed an online survey consumers addressing broad range issues regarding delta-8-THC, including treatment health conditions. Previous cannabis informed components. Results: Patterns had both similarities with differences from products. Administration methods were primarily edibles (64%) vaping concentrates (48%). About half participants (51%) used treat conditions, anxiety panic attacks (69%), stress (52%), depression bipolar disorder (46%), chronic pain (41%). Participants compared very favorably pharmaceutical drugs reported substantial levels substitution both. Most did not inform their primary care provider (78%) confident provider's ability integrate into (70%). Knowledge effective dosages was low, participants' knowledge Internet own experiences. Conclusion: Harm reduction central component public health. Although legal environment becoming more restrictive comparison delta-9-THC, results suggest that may be equally desired purposes lower undesirable adverse effects. All policies practices should by empirical evidence. Considerable will needed systematically verify patterns collaborations among academic researchers, government, industry valuable developing base other cannabinoids.

Language: Английский

---

The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 5749 - 5749

Published: May 25, 2024

Neurological disorders present a wide range of symptoms and challenges in diagnosis treatment. Cannabis sativa, with its diverse chemical composition, offers potential therapeutic benefits due to anticonvulsive, analgesic, anti-inflammatory, neuroprotective properties. Beyond cannabinoids, cannabis contains terpenes polyphenols, which synergistically enhance pharmacological effects. Various administration routes, including vaporization, oral ingestion, sublingual, rectal, provide flexibility treatment delivery. This review shows the efficacy managing neurological such as epilepsy, neurodegenerative diseases, neurodevelopmental disorders, psychiatric painful pathologies. Drawing from surveys, patient studies, clinical trials, it highlights alleviating symptoms, slowing disease progression, improving overall quality life for patients. Understanding mechanisms can open up possibilities using this plant individual needs.

Language: Английский

---

Using ecological momentary assessment to quantify Δ‐9‐tetrahydrocannabinol and cannabidiol use across different forms of cannabis: Feasibility in a sample of Canadian young adults reporting frequent cannabis use

Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

To establish the feasibility of using ecological momentary assessment (EMA) to estimate total quantities Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) used across different forms cannabis, assess predictive validity THC estimates for predicting acute cannabis-related consequences. 14-day EMA a smartphone application cannabis use in real time. Canada. Targeted sample n = 42 young adults (59.52% women, mean age 25 years) reporting frequent use. Surveys completed immediately prior assessed quantities, content CBD various be current session; participants also uploaded photos product labels when available. administered at fixed times throughout day (84.81% completion rate) Participants 786 pre-cannabis surveys, which 79.39% 77.35% contained sufficient information calculate (in milligrams), respectively. High agreement was observed between participant-entered contents those shown corresponding labels. Aggregating all products used, reported an average 141.41 [standard deviation (SD) 224.62, range 0.00-2000.00] milligrams (i.e. 28.28 standard five-milligram units) 7.53 (SD 34.87, 0.00-484.22) per day. Multilevel models revealed that were more likely report negative consequences following sessions their estimated higher than typical At between-person level, on less overall. Using appears feasible, with preliminary

Language: Английский

---

Healthcare practitioner perceptions on barriers impacting cannabis prescribing practices

BMC Complementary Medicine and Therapies, Journal Year: 2022, Volume and Issue: 22(1)

Published: Sept. 8, 2022

Canadians seeking medical cannabis (MC) may encounter difficulties in finding a healthcare provider (HCP) who authorizes their access to it. Barriers that HCPs face authorizing MC are unclear. The objectives of this study were evaluate HCP opinions, knowledge, comfort, and practice prescribing counseling on recreational use, whether the COVID-19 pandemic affected practices.Eligible participants included (e.g., attending physicians, nurses, pharmacists) Canada. A questionnaire evaluating was designed based instruments developed previous studies. Between April 13th-December 13th 2021, ninety-one associations asked distribute survey members, an advertisement placed online Canadian Medical Association Journal. Descriptive statistics used analyze results.Twenty-four organizations agreed disseminate 70 individuals completed Of respondents, 71% physicians or residents, while remainder pharmacists other HCPs. Almost none (6%) received training professional school but 60% did receive workshops, conferences). Over half (57%) more questions regarding since legalized, 82% reported having patients use MC. However, 56% felt uncomfortable ambivalent knowledge MC, 27% unfamiliar with requirements for obtaining most common symptoms recommending pain nausea, whereas conditions it cancer intractable pain. strongest barrier uncertainty safe effective dosage routes administration. lack research evidence demonstrating its safety efficacy. During pandemic, many respondents greater number relieve anxiety depression.Our results suggest across Canada responded our topics related barriers appear be clinical research, Increasing training, help feel equipped make informed treatment/prescribing decisions, which improve

Language: Английский

---

Planting the seeds for success: A qualitative study exploring primary healthcare providers’ perceptions about medical cannabis

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(3), P. e0295858 - e0295858

Published: March 7, 2024

Background In Canada, cannabis legalization altered the way that public can access for medical purposes. However, Canadians still struggle with finding healthcare professionals (HCPs) who are involved in counselling and authorization. This raises questions about barriers causing this breakdown care. Our study explored perceptions of primary care providers regarding their practice. Methods Semi-structured interviews were conducted by Zoom HCPs Newfoundland Labrador (NL) to discuss experiences non-medical Family physicians nurse practitioners practicing NL included. The interview guide coding template developed using Theoretical Domains Framework (TDF). A thematic analysis across TDF was then conducted. Results Twelve participants diverse demographic backgrounds experience levels interviewed. Five main themes emerged including, knowledge acquisition, internal influences, patient external HCP systemic influences. domain resulting greatest representation codes environmental context resources. Interpretation findings suggested have significant gaps authorizing cannabis, which limited practice competence confidence area. Referring patients clinics, while enforcing harm-reduction strategies, an interim option developing guidelines educational resources as prominent facilitators promote authorization within system.

Language: Английский

---

International perspectives on physician knowledge, attitudes, and practices related to medical cannabis

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13

Published: Feb. 20, 2025

The trends of recreational use cannabis and the for medical indications (i.e., "medical cannabis") have grown in recent years. Despite that, there is still limited scientific evidence to guide clinical decision-making, strength currently considered be low. In contrast, growing negative health outcomes related cannabis. this rapidly shifting landscape, role physician attitudes regarding therapeutic value has become essential. This study aimed characterize knowledge/experience, attitudes, potential predictors practice We conducted a cross-sectional survey physicians from 17 countries between 2016 2018. consisted questions designed explore knowledge, attitude, practices Descriptive statistics were used examine willingness recommend psychiatric indications, followed by regression analysis identify A total 323 responded survey, among which 53% women. mean age was 35.4 ± 9.5 years, with 10.04 8.6 years experience. Clinical experience overall (51.4% noted never having recommended 33% inadequate knowledge cannabis). majority respondents (84%) recognized risk psychosis use, while only 23% correctly identified addiction daily use. Overall, highest chemotherapy-induced nausea (67%), refractory chronic neuropathic pain (52%), spasticity amyotrophic lateral sclerosis (ALS; 51%). international examining revealed that are significant gaps domain-specific There wide variability cannabis, not consistent current evidence. thus highlights need greater education about

Language: Английский

---

Healthcare Professionals’ Perceptions About Medical Cannabis in Greece: A Qualitative Study

Journal of Market Access & Health Policy, Journal Year: 2025, Volume and Issue: 13(2), P. 13 - 13

Published: April 2, 2025

Background: Medical cannabis continues to generate interest as a potential therapeutic option, yet its acceptance in clinical practice faces challenges, including regulatory barriers, social stigma, and gaps scientific evidence. Methods: This study explores the perspectives of Greek medical doctors pharmacists on cannabis—key stakeholders application—through semi-structured interviews with 12 participants from each profession. Results: expressed range views cannabis, many acknowledging while emphasizing need for rigorous, disease-specific research. highlighted lack consistent trials, concerns about drug interactions, fine line between use misuse. Pharmacists echoed these concerns, citing inconsistencies standardized dosing. Both groups agreed that stigma misinformation hinder adoption, advocating targeted education transparent research communication. Participants indicated barriers also pose calls harmonized policies phased market entry approaches. Effective communication strategies, digital outreach clear messaging, were suggested differentiate recreational improve trust among healthcare providers patients. urgent collaboration policymakers, researchers, professionals establish credible option. Conclusion: The insights gained provide actionable recommendations bridge existing emphasize responsible, evidence-based approach

Language: Английский

---

Medicinal Cannabis Guidance and Resources for Health Professionals to Inform Clinical Decision Making

Clinical Therapeutics, Journal Year: 2023, Volume and Issue: 45(6), P. 527 - 534

Published: June 1, 2023

Language: Английский

---

Physicians' Attitudes and Practices Regarding Cannabis and Recommending Medical Cannabis Use

Cannabis and Cannabinoid Research, Journal Year: 2023, Volume and Issue: 9(4), P. e1048 - e1055

Published: April 25, 2023

Introduction: Medical cannabis users tend not to trust or rely on health care providers regarding advice. Previous surveys of physicians have focused favorability toward medical cannabis. The current study assesses how interact with patients in their day-to-day practice, and whether they address important topics such as use patterns substituting for medications. We predicted that would generally perceive dispensary staff caretakers competent addressing patient needs be likely recommendations. Methods: Physicians a university-affiliated system completed an anonymous online survey. survey assessed physicians' related education experiences, perceptions knowledge competence cannabis, the content discussions patients. also examined sources influence attitudes caregivers (MCCs). Results: A few (10%) had ever signed authorization form patients, consistent low this area. Discussions primarily focus risks (63%) rather than dosage (6%) harm reduction (25%). see weak compared other information unfavorable MCCs. Conclusion: Greater integration is needed at all levels clinical potential if receive no guidance. Continued research provide strong scientific basis developing treatment guidelines standardized use.

Language: Английский

---

Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real-World Cannabinoid Applications in Sport

Sports Medicine, Journal Year: 2024, Volume and Issue: 54(11), P. 2743 - 2769

Published: Aug. 21, 2024

Language: Английский

---